As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Pharma powerhouse names Cecile Guegan interim finance chief
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Subscribe To Our Newsletter & Stay Updated
